MC 838
RN given refers to Ca[2:1]salt(R-(R*,S))-isomer; structure given in first source
Also Known As:
MC-838; N-(3-N-cyclohexanecarbonyl-alanylthio)-2-(methylpropanoyl)proline calcium; altiopril calcium
Networked: 3
relevant articles (0 outcomes,
0 trials/studies)
Bio-Agent Context: Research Results
Related Diseases
1. | Hypotension (Low Blood Pressure)
04/01/1989
- " With the development of the hypotension, MC-838 significantly reduced ACE activity in the lung, kidney and aorta, but not in the brain and heart. " 04/01/1989
- " MC-838 (3 mg kg-1) given orally to SHRs elicited a long-lasting hypotension lasting over 24 h. " 03/01/1986
- " Captopril (0.01, 0.03, 0.1 and 0.3 mg/kg, i.v.) also caused a dose-related decrease in aortic pressure, but the significant hypotension appeared more rapidly than that of MC-838. " 03/01/1986
- " When administration of MC-838 (3.0 mg/kg) was repeated three times at a 30 min-interval, the second and third injections caused no additional hypotension, while each of the repeated injections of captopril (0.3 mg/kg) produced significant hypotension. " 03/01/1988
- " However, MC-838 and captopril, unlike hydralazine, did not significantly produce hypotension in DOCA-salt hypertensive rats. "
|
2. | Hypertension (High Blood Pressure)
|
|
Related Drugs and Biologics
Related Therapies and Procedures